Press Releases

SUNNYVALE, Calif., Jan. 8, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the

JERSEY CITY, N.J., Jan. 8, 2020 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from its second interim efficacy analysis of the ongoing Phase 3 open-label FURI study. The study is evaluating oral ibrexafungerp as a salvage

CHICAGO, Jan. 8, 2020 /PRNewswire/ -- No elevator.  No escalator.  Today, people all over the country will be ditching their morning elevator ride to take the stairs in honor of National Take the Stairs Day – reminding us all that a healthy lifestyle is achieved just one step at a time. The American Lung Association is calling on those stair-steppers

CHICAGO and PLEASANTON, Calif., Jan. 8, 2020 /PRNewswire/ -- Vyaire Medical, Inc. and Spirosure, Inc. have entered a five-year agreement for Vyaire to exclusively distribute Spirosure's Fenom Pro™ Asthma monitor in the

CARLSBAD, Calif., Jan. 8, 2020 /PRNewswire/ -- The n-Lorem Foundation announced today its official launch as a nonprofit organization established to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with ultra-rare diseases. The n-Lorem Foundation is being established with an initial investment by fo

OSLO, Norway, Jan. 8, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid tumors, today announces that it has entered into an exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development

CAMBRIDGE, Mass., Jan. 8, 2020 /PRNewswire/ -- Revitope Oncology, Inc., a cancer therapeutics company advancing a novel class of tumor-specific bispecific antibody therapies, today announced the appointment of Steve Arkinstall, D.Phil., as Chief Executive Officer. Dr. Arkinstall brings more than 30 years of experience in biopharmaceutical r

OLDWICK, N.J., Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt brings 18 years of commercial experience in the biotechnology sector, most recently se

CARY, N.C. and BASEL, Switzerland and WAYNE, Pa., Jan. 8, 2020 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceut

NEW YORK and BASEL, Switzerland, Jan. 8, 2020 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders, today announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designatio